Enliven Therapeutics, Inc. (ELVN)
D
Pipeline Grade
Financial Position (from SEC Filings)
$132.2M
Cash & Equivalents
$19.3M
Quarterly Burn Rate
21 mo
Est. Cash Runway
$3,650M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2027-01-01 | Phase1 Readout | — |
Active Clinical Trials (2)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05650879 | ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer | PHASE1 | Active Not Recruiting | 198 |
| NCT06328738 | ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer | PHASE1 | Active Not Recruiting | 275 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-06-11 | 8-K | Enliven Therapeutics, Inc. (ELVN) (CIK 0001672619) - EX-99.1 | EDGAR |